International Clinical Trial: HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong

Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07530198) titled 'HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong' on April 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Immuno Cure Holding (HK) Limited

Condition: Human Immunodeficiency Virus Human Immunodeficiency Virus I Infection

Intervention: Biological: ICVAX (TERESA-EPT I device) Biological: ICVAX (PharmaJet Tropis device)

Recruitment Status: Recruiting

Phase: Phase 1

Date of First Enrollment: March 30, 2026

Target Sample Size: 22

Countries of Recruitme...